Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · Real-Time Price · USD
3.070
-0.040 (-1.29%)
At close: Aug 1, 2025, 4:00 PM
3.026
-0.044 (-1.43%)
After-hours: Aug 1, 2025, 6:42 PM EDT

Company Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.

The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer.

The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Puma Biotechnology, Inc.
Puma Biotechnology logo
CountryUnited States
Founded2010
IndustryBiotechnology
SectorHealthcare
Employees172
CEOAlan Auerbach

Contact Details

Address:
10880 Wilshire Boulevard, Suite 2150
Los Angeles, California 90024
United States
Phone424 248 6500
Websitepumabiotechnology.com

Stock Details

Ticker SymbolPBYI
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001401667
CUSIP Number74587V107
ISIN NumberUS74587V1070
Employer ID77-0683487
SIC Code2834

Key Executives

NamePosition
Alan H. AuerbachFounder, Chairman, President, Chief Executive Officer and Secretary
Maximo F. NouguesChief Financial Officer and Principal Accounting Officer
Douglas Hunt B.Sc., FRAPSChief Regulatory Affairs, Medical Affairs, Pharmacovigilance and Law Officer
Mariann OhanesianSenior Director of Investor Relations

Latest SEC Filings

DateTypeTitle
Jul 18, 2025144Filing
Jul 9, 2025144Filing
Jul 9, 2025144Filing
Jul 9, 2025144Filing
Jul 8, 2025144Filing
Jul 8, 2025144Filing
Jul 8, 2025144Filing
Jun 24, 20258-KCurrent Report
Jun 13, 2025144Filing
Jun 13, 2025144Filing